Empowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
List view / Grid view
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.